Medtronic

In 2008 Scil Technology concluded a development, licensing and supply agreement with Medtronic Inc. for Scil Technology’s biologic dental regenerative materials for use in dental implant bone restoration and treatment of periodontal disease.
Under this agreement Medtronic Inc. is responsible for further clinical trials, regulatory approvals and commercialization.
www.medtronic.com

Sanofi

In 2011 Scil Technology has exclusively licensed its program for the regenerative treatment of osteoarthritis and cartilage disorders to Sanofi.
www.sanofi.com